ABSTRACT
Papillary Thyroid Carcinoma ...........................................................................713 26.3.2 Noninvasive Molecular Biomarkers Currently Used and under Development:
Serum Biomarkers in PTC ...............................................................................................717 26.3.2.1 Circulating TSH ................................................................................................717 26.3.2.2 TSH-R mRNA ..................................................................................................718 26.3.2.3 Tg mRNA ..........................................................................................................718 26.3.2.4 Proteomic Markers ...........................................................................................718 26.3.2.5 Epigenetic Markers ...........................................................................................719 26.3.2.6 miRNA Markers ...............................................................................................719 26.3.2.7 Runx2 mRNA .................................................................................................. 720 26.3.2.8 Circulating DNA .............................................................................................. 720 26.3.2.9 Galectin ............................................................................................................ 720
26.4 Integrative Omics-Based Molecular Markers for Early Diagnosis, Prognosis, and Therapy ......721 26.4.1 BRAF ................................................................................................................................721
